Method for preparation of 1-((3s,4r)-3-((2-((1-ethyl-1h-pyrazol-4-yl)amino)-7h-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one, and intermediate compounds thereof

HK40137482APending Publication Date: 2026-09-11DAEWOONG PHARM CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
HK62026126334
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-16
Filing Date
2026-07-17
Publication Date
2026-09-11
Patent Text Reader

Abstract

The present disclosure relates to a process for the preparation of 1-((3S, 4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl) amino)-7H-pyrrolo [2, 3-d] pyrimidin-4-yl) oxy)-4-fluoropiperidin-1-yl) prop-2-en-1-one and an intermediate compound thereof.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480077110.X (22) Application Date 2024.12.05 (30) Priority Data 10-2023-0174736 2023.12.05 KR 10-2024-0006933 2024.01.16 KR (85) PCT International Application Entering National Phase Date 2026.06.04 (86) PCT International Application Application Data PCT / KR2024 / 019811 2024.12.05 (87) PCT International Application Publication Data WO2025 / 121899 KO 2025.06.12 (71) Applicant: Daewoong Pharmaceutical Co., Ltd. Address: 35-14, 4-ga, Hyangnam-eup Pharmaceutical Industrial Park, Hwaseong-si, Gyeonggi-do, South Korea (72) Inventors: Park Joon-seok, Hyun Hae-jung, Lee Sun-hwan, Jeon Seon-ah, Kim Nam-yoon, Kim Won-sun, Kim Cheol-woong (74) Patent Agency: Beijing Patern Intellectual Property Agency Co., Ltd. 11270 Patent Attorneys: Zhao Guifang, Xu Chuan (51) Int.Cl. C07D 487 / 04 (2006.01) A61K 31 / 519 (2006.01) (54) Invention Title: 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)- Method for preparing 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one and intermediate compounds thereof.Claims 5 pages, Description 19 pages, CN 122341609 A 2026.07.03 CN 1 22 34 16 09 A 1. A method for preparing a compound represented by the following chemical formula 1, the method comprising: (step 1) reacting a compound represented by the following chemical formulas 1-1 with a compound represented by the following chemical formulas 1-2 in the presence of a base to prepare a compound represented by the following chemical formulas 1-3; (step 2) reacting a compound represented by the following chemical formulas 1-3 with a compound represented by the following chemical formulas 1-4 in the presence of a palladium catalyst and a base to prepare a compound represented by the following chemical formulas 1-5; (step 3) reacting a compound represented by the following chemical formulas 1-5 with an acid to prepare a compound represented by the following chemical formulas 1-6; and (step 4) reacting a compound represented by the following chemical formulas 1-6 with a compound represented by the following chemical formulas 1-7 in the presence of a base to prepare a compound represented by the following chemical formula 1; Wherein, at least one of steps 1 to 4 further comprises a crystallization step: [Chemical Formula 1] [Chemical Formula 1-1] [Chemical Formula 1-2] [Chemical Formula 1-3] [Chemical Formula 1-4] [Chemical Formula 1-5] Claims 1 / 5 Page 2 CN 122341609 A [Chemical Formula 1-6] [Chemical Formula 1-7] Wherein, in chemical formulas 1-1 to 1-7, P1 refers to a protecting group. 2. The preparation method according to claim 1, wherein, in step 1, based on 1 equivalent of the compound represented by chemical formula 1-1, the compound represented by chemical formula 1-2 is used in an amount of 0.1 to 10 equivalents. 3. The preparation method according to claim 1, wherein, in step 1, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. 4. The preparation method according to claim 1, wherein, in step 1, the base is used in an amount of 0.1 to 10 equivalents based on 1 equivalent of the compound represented by formula 1-1. 5. The preparation method according to claim 1, wherein, in step 1, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).6. The preparation method according to claim 5, wherein in step 1, the reaction is carried out at 30 to 60°C. 7. The preparation method according to claim 1, wherein, after the compound represented by chemical formula 1-1 reacts with the compound represented by chemical formula 1-2 in the presence of a base, step 1 further comprises a step of crystallizing the reaction product. 8. The preparation method according to claim 1, wherein, in step 2, based on 1 equivalent of the compound represented by chemical formula 1-3, the compound represented by chemical formula 1-4 is used in an amount of 0.1 to 10 equivalents. 9. The preparation method according to claim 1, wherein, in step 2, the palladium catalyst is at least one selected from the group consisting of: tris(dibenzylacetone)palladium(O), tetra(triphenylphosphine)palladium(O), bis[tris(2-methylphenyl)phosphine]palladium, palladium acetate(II), 1,1-(bis(diphenylphosphino)ferrocene)palladium(II), and palladium(II) chloride. 10. The preparation method according to claim 1, wherein, in step 2, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. 11. The preparation method according to claim 1, wherein, in step 2, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, sec-butanol, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, tert-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, xylene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). 12. The preparation method according to claim 1, wherein the reaction in step 2 is carried out at 80 to 100°C. 13. The preparation method according to claim 1, wherein, in step 3, the acid is at least one selected from the group consisting of: hydrochloric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, bromic acid, sulfuric acid, nitric acid, and iodic acid.14. The preparation method according to claim 1, wherein, in step 3, the reaction is carried out in one or more organic solvents selected from the group consisting of: ethyl acetate, dichloromethane, butyl acetate, chloroform, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). 15. The preparation method according to claim 1, wherein the reaction in step 3 is carried out at a temperature between 0°C and 50°C. 16. The preparation method according to claim 1, wherein, after reacting the compounds represented by chemical formulas 1-5 with an acid, step 3 further comprises a step of crystallizing the reaction product. 17. The preparation method according to claim 1, wherein, in step 4, the compound represented by chemical formula 1-7 is used in an amount of 0.1 to 10 equivalents based on 1 equivalent of the compound represented by chemical formula 1-6. 18. The preparation method according to claim 1, wherein, in step 4, the base is at least one selected from the group consisting of: potassium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, diisopropylamine, diisopropylethylamine, sodium bicarbonate, potassium bicarbonate, cesium carbonate, sodium carbonate, sodium methoxide, and potassium butyrate. 19. The preparation method according to claim 1, wherein the reaction in step 4 is carried out at -10°C to 50°C. 20. The preparation method according to claim 1, wherein, after reacting the compound represented by chemical formula 1-6 with the compound represented by chemical formula 1-7 in the presence of a base, step 4 further comprises a step of crystallizing the reaction product. 21. A method for preparing a compound represented by the following chemical formula 1, the method comprising a compound represented by the following chemical formulas 1-5 as an intermediate: [Chemical Formula 1] [Chemical Formulas 1-5] wherein in chemical formulas 1-5, P1 refers to a protecting group. 22. The preparation method according to claim 21, wherein P1 is tert-butoxycarbonyl (Boc). 23. A compound represented by the following chemical formulas 1-5, [Chemical Formulas 1-5] Claims 4 / 5 Page 5 CN 122341609 A wherein in chemical formulas 1-5, P1 refers to a protecting group. 24. The compound according to claim 23, wherein P1 is tert-butoxycarbonyl (Boc).Claims 5 / 5 Page 6 CN 122341609 A 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one and intermediate compounds thereof Technical Field

[0001] Cross-reference to related applications This application claims priority and benefit to Korean Patent Application No. 10-2023-0174736 filed on December 5, 2023 and Korean Patent Application No. 10-2024-0006933 filed on January 16, 2024, the entire contents of which are incorporated herein by reference.

[0002] This disclosure relates to a method for preparing 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one and intermediate compounds thereof. Background Art

[0003] Protein kinases are enzymes that catalyze the phosphorylation of specific residues of other proteins and play an important role in signal transduction pathways that transduce extracellular signals to the cell nucleus. Furthermore, they are involved in a variety of diseases in the body. There is considerable evidence that T cells (or T lymphocytes) and B cells (or B lymphocytes) play important roles in the pathogenesis or development of inflammatory diseases, autoimmune diseases, proliferative or hyperproliferative diseases and / or immune-mediated diseases.

[0004] Janus kinase (hereinafter “JAK”) is a cytoplasmic protein tyrosine kinase that plays a key role in regulating cellular function in the lymphohematopoietic system. Cytokines are known to play important roles in regulating inflammation, immunity, and normal cellular function, and JAK activates STAT (signal transducer and activator of transcription) proteins through tyrosine phosphorylation to provide a rapid signal transduction pathway for cytokines. JAK / STAT signaling is known to be associated with allergies, asthma, autoimmune diseases (e.g., transplant rejection, rheumatoid arthritis, amyotrophic lateral sclerosis, multiple sclerosis, etc.), solid tumors, and blood cancers (e.g., leukemia, lymphoma, etc.).

[0005] The JAK family is divided into four members: JAK1, JAK2, JAK3, and TYK2. Members of the JAK family pair up to mediate signals from various cytokines. It includes JAK2 and JAK1, which are associated with hematopoietic growth factor signaling, and the combination of TYK2 and JAK2 is important for interferon signaling and contributes to host tolerance. JAK2 can induce anemia, thrombocytopenia, and leukopenia, especially when JAK2 is involved in hematopoietic growth factor signaling and causes excessive inhibition.

[0006] JAK1, JAK2, and TYK2 have been found to be widely expressed, while JAK3 expression is confined to lymphocytes and is associated with signaling of the common γ chain of members of the IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors, particularly the common γ chain of the IL-2 family. Once a cytokine binds, the receptor carries an adjacent JAK3, which induces autophosphorylation of the C-terminus of the β-chain. As a result, it causes activation of STAT proteins, a crucial step in retransmitting signals back to the nucleus. JAK3 controls signaling pathways for multiple cytokines through this process. This makes JAK3 an attractive target for immunosuppression.

[0007] B cells play an important role in the development of autoimmune diseases and / or inflammatory diseases. Protein-based therapeutics that reduce B cells, such as Rituxan, are effective for autoantibody-induced inflammatory diseases, such as rheumatoid arthritis. Therefore, protein kinase inhibitors that act on B cell activation are useful therapeutic agents for treating B cell-mediated diseases, such as those that produce autoantibodies. Instructions for Use, Page 1 / 19, CN 122341609 A

[0008] Signal transduction via the B cell receptor (BCR) regulates various B cell responses, including proliferation and differentiation into mature antibody-producing cells. The BCR is an important regulator of B cell activity, and abnormal signal transduction can lead to the formation of pathogenic autoantibodies, which causes various autoimmune and / or inflammatory diseases and the proliferation of dysregulated B cells.

[0009] Bruton's tyrosine kinase (hereinafter referred to as "BTK") is an important regulator of B cell development, activation, signal transduction, and survival. BTK participates in signal transduction pathways initiated by binding various extracellular ligands to their cell surface receptors. BTK activity, acting simultaneously with protein tyrosine kinases Lyn and Syk after linking to the B cell antigen receptor (BCR), is essential for inducing phospholipase C-γ2-mediated calcium mobilization. Therefore, inhibiting BTK may be a useful therapeutic approach to block the pathogenesis of B cell-mediated diseases.

[0010] As described above, Janus kinase and TEC-based kinases play important roles in the activation of T cells and / or B cells associated with the development of inflammatory diseases, autoimmune diseases, proliferative or hyperproliferative diseases, and immune-mediated diseases. Therefore, the development of substances that effectively inhibit these diseases can be used as relevant therapeutic agents. Specific examples of diseases that can be treated and prevented include cancer, transplant rejection, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, psoriasis, asthma, allergic dermatitis, atopic dermatitis, eczema, type 1 diabetes, diabetic complications, ulcerative colitis, Crohn's disease, autoimmune thyroid disease, generalized alopecia, Sjögren's syndrome, etc.

[0011] The JAK3 kinase inhibitor tofacitinib (CP-690550) (Pfizer) is currently approved and marketed for the treatment of rheumatoid arthritis. In addition, the BTK kinase inhibitor ibrutinib (PCI-32765) (Pharmacyclics) is in the clinical stage, but serious side effects such as rash and diarrhea have been reported in clinical cases. Therefore, there is a need to develop a more stable and effective substance that inhibits JAK and / or BTK (see Nat Rev Rheumatol. 2009 Jun 5(6) 317-24; Expert Opin Investig Drugs. 2014 Aug 23(8) 1067-77; Drug Discov Today 2014 Aug 19(8) 1200-4; WO2002 / 096909; WO2010-009342).

[0012] Therefore, the inventors have discovered that oxy-fluoropiperidine derivatives (which have chemical structures different from those of kinase inhibitors reported to date) exhibit excellent inhibitory activity as kinase inhibitors. In this regard, the inventors have conducted in-depth research on methods for preparing novel oxy-fluoropiperidine derivatives, and have found that the preparation method described below can be commercially mass-produced, and further reduces impurities while improving overall yield and quality, thus completing this disclosure. Summary of the Invention

[0013] [Technical Problem] The object of this disclosure is to provide a method for preparing 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-yl)propyl-2-en-1-one.

[0014] Another object of this disclosure is to provide a method for preparing tartrate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0015] Another object of this disclosure is to provide a novel intermediate compound obtained in the preparation of phosphate of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one.

[0016] [Technical Solution] In order to achieve the above objectives, a method is provided for preparing tartrate of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one (a compound represented by the following chemical formula 1). More specifically, the preparation method includes the following steps, wherein at least one of steps 1 to 4 under page 2 / 19 of the specification, CN 122341609 A, further includes a crystallization step: (Step 1) reacting a compound represented by chemical formula 1-1 with a compound represented by chemical formula 1-2 in the presence of a base to prepare a compound represented by chemical formula 1-3; (Step 2) reacting a compound represented by chemical formula 1-3 with a compound represented by chemical formula 1-4 in the presence of a palladium catalyst and a base to prepare a compound represented by chemical formula 1-5; (Step 3) reacting a compound represented by chemical formula 1-5 with an acid to prepare a compound represented by chemical formula 1-6; and (Step 4) reacting a compound represented by chemical formula 1-6 with a compound represented by chemical formula 1-7 in the presence of a base to prepare a compound represented by chemical formula 1; [Chemical Formula 1]

[0017] [Chemical Formula 1-1]

[0018] [Chemical Formula 1-2]

[0019] [Chemical Formula 1-3]

[0020] [Chemical Formula 1-4]

[0021] [Chemical Formula 1-5] Specification 3 / 19 Page 9 CN 122341609 A

[0022] [Chemical Formula 1-6]

[0023] [Chemical Formula 1-7]

[0024] Wherein in Chemical Formulas 1-1 to 1-7, P1 refers to a protecting group.

[0025] This document further provides a method for preparing a compound represented by the following Chemical Formula 1, the method comprising a compound represented by the following Chemical Formulas 1-5 as an intermediate: [Chemical Formula 1]

[0026] [Chemical Formula 1-5] Specification 4 / 19 Page 10 CN 122341609 A

[0027] Wherein in Chemical Formulas 1-5, P1 refers to a protecting group.

[0028] Further, compounds represented by the following chemical formulas 1-5 are provided: [Chemical Formulas 1-5]

[0029] Wherein in chemical formulas 1-5, P1 refers to a protecting group.

[0030] This preparation method does not involve a substitution reaction of the protecting group alone, thus shortening the process steps compared to conventional preparation methods. The preparation method also does not involve a column purification step, thus improving the yield and / or purity of the final product. Furthermore, this preparation method involves crystallization purification in at least one step, which is beneficial for large-scale production.Furthermore, this preparation method does not use previously used explosive strong bases (such as NaH), thus ensuring safety during the process, and the reaction temperature in some steps is lower than before, which is beneficial for application in general production plants and has economic benefits.

[0031] The compound represented by chemical formula 1 is prepared by the following reaction scheme 1: [Reaction Scheme 1] Specification 5 / 19 pages 11 CN 122341609 A

[0032] In reaction scheme 1, P1 refers to a protecting group.

[0033] More specifically, P1 can be any protecting group selected from the group consisting of: tert-butoxycarbonyl (Boc), carbapenyloxy (Cbz), p-methoxybenzylcarbonyl (Moz), 9-fluorenylmethoxycarbonyl (Fmoc), acetyl (Ac), benzoyl (Bz), benzyl (Bn), and p-methoxybenzyl (PMB).

[0034] Meanwhile, the various steps described below may further include a post-reaction purification step to prepare compounds with high purity and yield. In one example of a purification method, extraction utilizing differences in solubility, adsorption using activated carbon and / or silica-based materials, filtration, precipitation, crystallization, etc., may be used. However, the purification method does not use column chromatography, which is unsuitable for large-scale production. Preferably, the purification step may be performed as described in each step.

[0035] Furthermore, each step may further include a crystallization step using a crystallization solvent as a final step. If a purification step is performed, the crystallization step may be performed after the purification step; and if no purification step is performed, the crystallization step may be performed after the reaction. By further including a crystallization step, large-scale production can be achieved. The crystallization solvent may be used depending on the product of each step, but there are no particular limitations. Preferably, the crystallization step may be performed as described in each step.

[0036] (Step 1) Step 1 is a step of reacting a compound represented by chemical formula 1-1 with a compound represented by chemical formula 1-2 in the presence of a base to prepare a compound represented by chemical formula 1-3. The reaction is a nucleophilic aromatic substitution reaction, which is carried out in the presence of a base so that the added compound represented by chemical formula 1-2 becomes a nucleophile.

[0037] In step 1, based on 1 equivalent of the compound represented by Formula 1-1, the compound represented by Formula 1-2 may be used in amounts from 0.1 to 10 equivalents. Specifically, based on 1 equivalent of the compound represented by Formula 1-1, the compound represented by Formula 1-2 may be used in amounts from 0.2 to 5 equivalents, 0.3 to 3 equivalents, 0.5 to 2 equivalents, 0.7 to 1.5 equivalents, 1 to 1.5 equivalents, 1 to 1.3 equivalents, 1 to 1.05 equivalents, or 1.05 equivalents.

[0038] Further, in step 1, the alkali may be at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. Of these alkalis, potassium tert-butoxide is preferably used in terms of reaction rate and yield. It is sufficient that the alkali used is a non-explosive alkali to ensure safety, which is beneficial for industrialization.

[0039] Moreover, based on 1 equivalent of the compound represented by chemical formula 1-1, the alkali can be used in amounts from 0.1 to 10 equivalents. In the specification, page 6 / 19, CN 122341609 A, preferably, based on 1 equivalent of the compound represented by chemical formula 1-1, the base can be used in amounts of 0.5 to 5 equivalents, 1 to 5 equivalents, 2 to 5 equivalents, 2 to 3 equivalents, or 3 equivalents. If too little base is used, there is a risk of prolonging the reaction time; and even if too much base is used, there is no difference in reaction time, so it is preferred to use base within the above range.

[0040] In step 1, the reaction can be carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). As an example, one type of solvent can be used, or a mixture of two or more types of solvents can be used. Preferably, 1,4-dioxane can be used as the organic solvent. The advantage of 1,4-dioxane is that it produces a higher purity product compared to other solvents and it is easy to separate during extraction. The disadvantage of other solvents is that they produce a relatively large amount of impurities or have a slow reaction rate.

[0041] Further, based on the weight of the compound represented by chemical formula 1-1, the organic solvent can be used in an amount of 5 to 30 times (mL / g), more specifically 5 to 15 times (mL / g).

[0042] Further, the reaction can be carried out at 30 to 60°C for 2 to 10 hours. If the reaction is carried out at temperatures below the above range and / or for a short reaction time, the reaction may not proceed sufficiently, which may result in a decrease in production yield. Furthermore, even if the reaction is carried out at temperatures above the above range and / or for a longer reaction time, the production yield will not increase substantially, which is undesirable in terms of process cost.

[0043] Meanwhile, after the reaction in step 1 is completed, the method may further include a purification step of extracting the reaction product using ethyl acetate and / or water.Specifically, ethyl acetate and water can be used to extract the reaction products. That is, after the reaction is complete, ethyl acetate and water can be used to extract the compounds represented by chemical formulas 1-3. The extraction using ethyl acetate and water can be carried out by stirring the mixture containing the reaction products and each solvent for 30 minutes or longer, letting it stand for 30 minutes or longer, and then separating the layers, thereby discarding the aqueous layer (lower layer) and taking the organic layer (upper layer). The extraction using ethyl acetate and water can be repeated once or multiple times. In the case of this extraction, compared with the case of extraction using a dichloromethane / water mixed solvent, impurities with a relative retention time of less than 1.0 separated by high performance liquid chromatography (HPLC) can be effectively removed through the aqueous layer.

[0044] Furthermore, step 1 may further include the step of filtering the extracted mixture and then performing vacuum concentration and / or azeotropic concentration. The vacuum concentration and / or azeotropic concentration steps are preferably performed after the extraction step with ethyl acetate and / or water.

[0045] Furthermore, step 1 may further include the step of crystallizing the reaction products to purify the compounds represented by chemical formulas 1-3. This crystallization step is preferably performed after the extraction and purification steps. In other words, step 1 can be performed by adding a crystallization solvent to the concentrated product after the extraction and purification steps and stirring at a temperature of about 20 to 50°C for 30 minutes to 4 hours to prepare the compound represented by chemical formulas 1-3.

[0046] When the reaction product is prepared by crystallization in this manner, unlike column chromatography which uses silica columns for purification, it can be applied industrially, which is advantageous for large-scale industrial production and has the advantage of obtaining high yields.

[0047] Specifically, the crystallization step can be performed by crystallization using water as the crystallization solvent. The crystallization step can be performed by repeating the crystallization process once or multiple times, in the order of adding the crystallization solvent and then stirring. In this way, when the crystallization process is repeated while adding the solvent multiple times rather than all at once, crystals that adhere to the wall surface during the solvent addition process can even be obtained, thereby preventing a decrease in yield, effectively removing residual byproducts after the reaction, and crystallizing uncrystallized products by repeating the crystallization process. Therefore, compared to purification processes using solvents such as ethyl acetate in the form of a slurry as described on page 7 / 19 of the specification, high-purity compounds can be obtained in high yield.

[0048] The crystallization solvent used in a crystallization process can be used in an amount of 3 to 20 times the volume (mL / g), more specifically, in an amount of 3 to 10 times the volume (mL / g), relative to the weight of the compound represented by chemical formula 1-1.

[0049] A crystallization process can be carried out by stirring for 10 minutes to 2 hours at a temperature range of 5 to 30°C, preferably at room temperature (20 to 25°C). The time of the process can be adjusted appropriately, for example, increasing the time of the process when the number of repetitions of the crystallization process is small, and decreasing the time of the process when the number of repetitions is large.

[0050] That is, when all the steps of purifying and crystallizing the reaction product in step 1 are performed to prepare the compound represented by chemical formulas 1-3, step 1 may include, but is not limited to, the following steps: reacting the compound represented by chemical formula 1-1 with the compound represented by chemical formula 1-2 in the presence of a base; adding ethyl acetate and water to discard the aqueous layer (lower layer) and separate and extract the organic layer (upper layer); and concentrating the purified mixture under vacuum and / or azeotropically; and crystallizing the concentrate.

[0051] After purifying the compounds represented by chemical formulas 1-3, the compounds may be dried at 40 to 60°C for 10 to 14 hours to reduce the water content in the compounds represented by chemical formulas 1-3. More specifically, if the water content of the compounds represented by chemical formulas 1-3 is significantly reduced by drying at 50 to 60°C, the conversion rate of the next step (i.e., step 2) can be increased.

[0052] (Steps 2 and 3) Step 2 is a step of reacting the compounds represented by chemical formulas 1-3 and 1-4 in the presence of a palladium catalyst and a base to prepare the compound represented by chemical formulas 1-5, wherein a Buchwald-Hartwig amination reaction is carried out. The Buchwald-Hartwig amination reaction is a reaction in which carbon and nitrogen bonds are formed by palladium-catalyzed coupling of an amine with an aryl halide. Furthermore, step 3 involves reacting the compounds represented by chemical formulas 1-5 with an acid to prepare the compounds represented by chemical formulas 1-6, a step used to remove the protecting group P1 contained in chemical formulas 1-5.

[0053] The concentrated residual liquid containing the compounds represented by chemical formulas 1-5 produced in step 2 can be used as is in the next step without a separate purification process to ensure a stable reaction without reducing yield or purity, etc. Therefore, considering the economic benefits of omitting the purification step and the ease and convenience of the process, steps 2 and 3 can be prepared in situ using the concentrated residual liquid of step 2 as is.

[0054] In step 2, based on 1 equivalent of the compounds represented by chemical formulas 1-3, compounds represented by chemical formulas 1-4 can be used in amounts from 0.1 to 10 equivalents.Specifically, based on 1 equivalent of the compound represented by chemical formulas 1-3, the compound represented by chemical formulas 1-4 can be used in amounts of 0.2 to 5 equivalents, 0.5 to 5 equivalents, 0.5 to 3 equivalents, 0.5 to 2 equivalents, 0.5 to 1.5 equivalents, 1 to 1.5 equivalents, or 1.5 equivalents.

[0055] In step 2, the palladium catalyst can be a palladium (0) catalyst in which the valence of palladium (Pd) in the compound is 0, or a palladium (II) catalyst in which the valence is +2. For example, the palladium catalyst can be at least one selected from the group consisting of: tris(dibenzylacetone)palladium (0), tetra(triphenylphosphine)palladium (0), bis[tris(2-methylphenyl)phosphine]palladium, palladium (II) acetate, 1,1-(bis(diphenylphosphine)ferrocene)palladium (II) chloride, and palladium (II) chloride.

[0056] Further, in step 2, the base may be at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate. It is sufficient that the base used is not an explosive base as described on page 8 / 19 of the specification (CN 122341609 A) to ensure safety, which is beneficial for industrialization.

[0057] Further, the reaction may be carried out in the presence of a phosphine-based compound, a palladium catalyst, and a base. As a phosphine-based compound, at least one selected from the group consisting of: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, 4,5-bis(diphenylphosphino)-9,9-dimethyloxanthracene, 2-(dicyclohexylphosphino)-3,6-dimethoxy-2,4'6'-triisopropyl-1,1'-biphenyl, 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl, and dicyclohexylphosphino-2',6'-diisopropoxybiphenyl.

[0058] Preferably, in step 2, based on 1 equivalent of the compound represented by formulas 1-3, the base may be used in an amount of 0.1 to 10 equivalents. Preferably, based on 1 equivalent of the compound represented by formulas 1-3, the base may be used in an amount of 0.5 to 5 equivalents, 1 to 5 equivalents, 2 to 5 equivalents, 3 to 5 equivalents, or 3 equivalents. If too little base is used, there is a risk of prolonging the reaction time; and even if too much base is used, there is no difference in reaction time, so it is preferable to use base within the above range.

[0059] As the reaction solvent in step 2, a solvent that is inactive in the amine substitution reaction can be used.For example, the reaction can be carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, sec-butanol, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, tert-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, xylene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). For example, one type of solvent can be used, or a mixture of two or more types of solvents can be used, but sec-butanol is preferred in terms of reaction rate and yield.

[0060] The organic solvent can be used in amounts of 0.5 to 10 times the volume (mL / g) relative to the weight of the compound represented by chemical formulas 1-3, specifically 4 to 8 times, or 4 to 6 times the volume (mL / g). If the solvent is in excess during the reaction in step 2, there is a problem that the reaction will not proceed.

[0061] Further, the reaction can be carried out at a temperature of 80 to 100°C for 1 to 10 hours. If the reaction is carried out at a temperature below the above range and / or for a short reaction time, the reaction may not proceed sufficiently, which may result in a decrease in production yield. Furthermore, even if the reaction is carried out at a temperature above the above range and / or for a long reaction time, the production yield does not increase substantially, which is not preferred in terms of process cost. More specifically, the reaction can be carried out at a temperature of 85 to 95°C or 88 to 92°C for 1 to 6 hours, 1 to 4 hours, preferably 1 to 3 hours, and more preferably 1.5 to 2 hours. The reaction temperature is in a range far below the boiling point of the reaction solvent, which is significantly lower than the conventional reaction temperature, thus making it easy to apply in the process and reducing time and cost.

[0062] Further, when using the above-described combination of palladium catalyst, base, and phosphine-based compound, the reaction can be carried out in a known reactor. Thus, step 2 can be applied as a step in a process for the large-scale production of the compound represented by Formula 1.

[0063] Simultaneously, after the reaction in step 2 is completed, the method may further include a purification step of extracting the reaction product using ethyl acetate and water or using an aqueous solution of ethyl acetate and sodium chloride. Specifically, the reaction product can be extracted using ethyl acetate and water, or using an aqueous solution of ethyl acetate and sodium chloride, or using both of the above methods. That is, after the reaction is completed, the compounds represented by chemical formulas 1-5 can be extracted using ethyl acetate and water or using an aqueous solution of ethyl acetate and sodium chloride. The extraction using ethyl acetate and water or using an aqueous solution of ethyl acetate and sodium chloride can be carried out by stirring the mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, thereby discarding the aqueous layer (lower layer) and taking the organic layer (upper layer).Extraction using ethyl acetate and water can be repeated once or multiple times. In this case of extraction, impurities with relative retention times less than 1.0, separated by high performance liquid chromatography (HPLC), can be effectively removed by the aqueous layer compared to extraction using a dichloromethane / water mixed solvent.

[0064] Further, step 2 may further include a step of vacuum concentration and / or azeotropic concentration of the extracted mixture. The vacuum concentration and / or azeotropic concentration step is preferably performed after the extraction step using an aqueous solution of ethyl acetate and water or ethyl acetate and sodium chloride.

[0065] That is, when all the steps of purifying the reaction product in step 2 are performed to prepare the compound represented by chemical formulas 1-5, step 2 may include, but is not limited to, the following steps: reacting the compound represented by chemical formulas 1-3 with the compound represented by chemical formulas 1-4 in the presence of a palladium catalyst and a base; adding ethyl acetate and water or adding an aqueous solution of ethyl acetate and sodium chloride to discard the aqueous layer (lower layer) and separate and extract the organic layer (upper layer); and vacuum concentrating and / or azeotropically concentrating the purified mixture.

[0066] Meanwhile, after the reaction is complete, the processes of step 2 and step 3 described below can be carried out in situ in the same reaction vessel without the need for purification or separation of the compound represented by chemical formulas 1-5. In this way, since the purification and separation of the compound in step 2 is not required, the method for preparing the compound represented by chemical formula 1, including step 2, can be advantageous for the large-scale industrial production of the compound.

[0067] Step 3 is a step of reacting the compounds represented by chemical formulas 1-5 with an acid to prepare the compounds represented by chemical formulas 1-6, which is a step of removing the protecting group P1 contained in chemical formulas 1-5.

[0068] As the acid used in the reaction of step 3, at least one selected from the group consisting of: hydrochloric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, bromic acid, sulfuric acid, nitric acid, and iodic acid can be used. Among these acids, hydrochloric acid is preferred when considering yield and cost. Here, concentrated hydrochloric acid (c-HCl) can be used as hydrochloric acid. For example, concentrated hydrochloric acid with a concentration of about 30 to 40 wt.% can be used.

[0069] The acid can be used in an amount of 1 to 10 times the volume (mL / g) relative to the weight of the compounds represented by chemical formulas 1-5, more specifically in an amount of 2 to 5 times the volume (mL / g).

[0070] The reaction solvent in step 3 may be one or more organic solvents selected from the group consisting of: ethyl acetate, dichloromethane, butyl acetate, chloroform, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO). As an example, one type of solvent may be used, or a mixture of two or more types of solvents may be used.

[0071] The organic solvent may be used in an amount of 5 to 30 times the volume (mL / g), more specifically 5 to 15 times, or 5 to 6 times the volume (mL / g), relative to the weight of the compound represented by formulas 1-5.

[0072] Further, the reaction can be carried out at 0°C to 50°C for 1 to 10 hours, preferably 3 to 5 hours. The removal reaction of the tert-butoxycarbonyl group (which is a protecting group) corresponds to a reaction that can be easily carried out without additional heat treatment and can be carried out within the above temperature range. However, if the reaction time is less than 1 hour, the reaction may not proceed sufficiently; if the reaction time exceeds 10 hours, the production yield will not increase substantially, so the above reaction time is preferred.

[0073] Meanwhile, after the reaction in step 3 is completed, the method may further include a purification step of extracting the reaction product. Preferably, there is no limitation on the solvent used for extraction, but as an example, the extraction step may use dichloromethane and water or ethyl acetate and water to extract the reaction product. That is, after the reaction is completed, the compound represented by chemical formulas 1-6 may be extracted using dichloromethane and water or ethyl acetate and water or both of the above methods.

[0074] Extraction using dichloromethane and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, thereby discarding the organic layer (lower layer) and taking the aqueous layer (upper layer). Extraction using ethyl acetate and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then separating the layers, thereby discarding the organic layer (lower layer) and taking the aqueous layer (upper layer). Extraction using dichloromethane and water or extraction using ethyl acetate and water can be repeated once or multiple times. Meanwhile, extraction using ethyl acetate and water is preferably carried out in the presence of a base such as sodium hydroxide, while maintaining the pH of the reaction product between 9 and 11.

[0075] Furthermore, step 3 may further include the step of vacuum concentration and / or azeotropic concentration of the extracted mixture.The vacuum concentration and / or azeotropic concentration steps are preferably carried out after extraction with dichloromethane and water, or ethyl acetate and water.

[0076] Moreover, step 3 may further include a step of crystallizing the reaction product to purify the compound represented by chemical formulas 1-6. This crystallization step is preferably carried out after the extraction and purification step. In other words, step 3 can be carried out by adding a crystallization solvent to the concentrated product after the extraction and purification step and stirring the mixture at a temperature of about 20 to 40°C for 30 minutes to 4 hours to prepare the compound represented by chemical formulas 1-6. Preferably, the crystallization step can be carried out at room temperature of 20 to 30°C or 20 to 25°C.

[0077] In this way, when the reaction product is prepared by crystallization using a crystallization solvent, unlike the case of purification using a silica column, it can be applied to industrial production, which is advantageous for large-scale industrial production and has the advantage of being able to obtain high yields.

[0078] Specifically, the crystallization step can be carried out by crystallization using methyl isobutyl ketone or n-heptane as a crystallization solvent. When using the two solvents mentioned above, there is no restriction on their order, but it is preferred to carry out the crystallization process using methyl isobutyl ketone followed by the crystallization process using n-heptane. The crystallization step can be carried out by repeating the crystallization process once or multiple times, in the order of adding the crystallization solvent and then stirring. In this way, when the crystallization process is repeated while adding the solvent multiple times rather than adding the solvent all at once, crystals that adhere to the wall surface during the solvent addition process can even be obtained, thereby preventing a decrease in yield and effectively removing residual byproducts after the reaction. In addition, the uncrystallized product can be crystallized by repeating the crystallization process. Thus, high-purity compounds can be obtained in high yield compared to purification processes using solvents such as ethyl acetate in slurry form.

[0079] The crystallization solvent used in a crystallization process can be used in an amount of 3 to 20 times the volume (mL / g) relative to the weight of the compound represented by chemical formulas 1-5, more specifically in an amount of 3 to 15 times the volume (mL / g). A crystallization process can be carried out by stirring for 10 minutes to 3 hours in the temperature range of 5 to 30°C. The time of this process can be adjusted appropriately. For example, when the number of repetitions of the crystallization process is small, the time of the process can be increased; when the number of repetitions is large, the time of the process can be decreased.

[0080] That is, when performing all the steps of purifying and crystallizing the reaction product in step 3 to prepare the compound represented by chemical formulas 1-6, step 3 may include, but is not limited to, the following steps: reacting the compound represented by chemical formulas 1-5 with an acid; adding water and dichloromethane to discard the organic layer (lower layer) and separating and extracting the aqueous layer (upper layer); adding water and ethyl acetate to discard the aqueous layer (lower layer) and separating the organic layer (upper layer); and concentrating the purified mixture under vacuum and / or azeotropically; and crystallizing the concentrate.

[0081] After crystallizing and purifying the compound represented by chemical formulas 1-6, the compound may be dried at 30 to 60°C for 10 to 14 hours to reduce the water content contained in the compound represented by chemical formulas 1-6. More specifically, if the moisture content of the compounds represented by chemical formulas 1-6 can be significantly reduced by drying at 50°C or lower, the conversion rate of step 11 / 19 of the next specification (i.e., step 4) can be increased.

[0082] (Step 4) Step 4 is an acrylic acidification reaction step, wherein the compounds represented by chemical formulas 1-6 are reacted with the compounds represented by chemical formulas 1-7 in the presence of a base to prepare the compound represented by chemical formula 1.

[0083] In step 4, based on 1 equivalent of the compound represented by chemical formulas 1-6, the compound represented by chemical formulas 1-7 can be used in amounts from 0.1 to 10 equivalents. Specifically, based on 1 equivalent of the compound represented by chemical formulas 1-6, compounds represented by chemical formulas 1-7 can be used in amounts of 0.2 to 5 equivalents, 0.5 to 5 equivalents, 0.5 to 3 equivalents, 0.5 to 2 equivalents, 0.5 to 1.5 equivalents, 1 to 1.5 equivalents, 1 to 1.1 equivalents, or 1.1 equivalents.

[0084] As the base used in the reaction of step 4, at least one selected from the group consisting of: potassium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, diisopropylamine, diisopropylethylamine, sodium bicarbonate, potassium bicarbonate, cesium carbonate, sodium carbonate, sodium methoxide, and potassium butyrate. Among these bases, potassium carbonate, sodium carbonate, sodium bicarbonate, or potassium bicarbonate is preferred in terms of the degree of completion of the reaction and the formation of byproducts.

[0085] A mixed solvent of tetrahydrofuran (THF) and water can be used as the solvent for this reaction. At this point, tetrahydrofuran can be used in an amount of 5 to 40 times or 5 to 10 times the volume (mL / g) relative to the weight of the compounds represented by chemical formulas 1-6, and water can be used in an amount of 2 to 10 times or 2 to 5 times the volume (mL / g).

[0086] Furthermore, the reaction in step 4 can be carried out at a temperature of -10°C to 50°C for 1 to 5 hours.Preferably, the reaction can be carried out at a temperature of 0°C or higher, more preferably at a temperature of 0°C or higher and 10°C or lower. Therefore, it is preferable to cool all reaction reagents, such as reactants and organic solvents, used to suppress the rise in reaction temperature during the reaction process to a temperature of 0°C or lower before use.

[0087] Meanwhile, after the reaction in step 4 is completed, the method may further include a purification step of extracting the reaction product. Specifically, ethyl acetate and water can be used to extract the reaction product. That is, after the reaction is completed, ethyl acetate and water can be used to extract the compound represented by chemical formula 1. Extraction using ethyl acetate and water can be carried out by stirring a mixture containing the reaction product and each solvent for 30 minutes or longer, allowing it to stand for 30 minutes or longer, and then performing layer separation, thereby discarding the aqueous layer (lower layer) and using the organic layer (upper layer). In this extraction case, compared to extraction using a dichloromethane / water mixed solvent, impurities with a relative retention time of less than 1.0, separated by high-performance liquid chromatography (HPLC), can be effectively removed to the aqueous layer. Furthermore, if necessary, activated carbon and / or silica-based materials can be used for the purification process to remove byproducts or foreign substances.

[0088] Furthermore, step 4 may further include filtering the organic layer containing the extracted mixture and then concentrating it under vacuum. This vacuum concentration step is preferably performed after the extraction step using ethyl acetate and / or water.

[0089] Preferably, step 4 may further include a step of crystallizing the reaction product to purify the compound represented by chemical formula 1. This crystallization step is preferably performed after the extraction purification and vacuum concentration steps. In other words, step 4 can be performed by adding a crystallization solvent to the concentrated product after the extraction purification step and stirring at a temperature of about 20 to 40°C for 30 minutes to 4 hours. Preferably, the crystallization step can be performed at room temperature of 20 to 30°C or 20 to 25°C. The time of this process can be appropriately adjusted by increasing the time of the process when the number of repetitions of the crystallization process is small and decreasing the time of the process when the number of repetitions is large.

[0090] When the reaction product is prepared by crystallization using a crystallization solvent in this manner, unlike the case of purification using a silica column, it can be applied to industrial applications, which is advantageous for large-scale industrial production and has the advantage of achieving high yields.

[0091] Specifically, the crystallization step can be carried out by crystallization using ethanol or n-heptane as the crystallization solvent. There is no restriction on the order in which these two solvents are used (pages 12 / 19 of the specification, CN 122341609 A). The crystallization step can be carried out by repeating the crystallization process once or multiple times, in the order of adding the crystallization solvent and then stirring.In this way, when the crystallization process is repeated with multiple additions of solvent instead of a single addition, crystals adhering to the wall surface during solvent addition can be obtained, thereby preventing yield reduction and effectively removing residual byproducts after the reaction. Furthermore, repeated crystallization processes can crystallize uncrystallized products. Thus, compared to purification processes using solvents in slurry form, high-purity compounds can be obtained in high yields.

[0092] The crystallization solvent can be used in an amount of 0.5 to 15 times the volume (mL / g), more specifically 0.5 to 10 times the volume (mL / g), relative to the weight of the compound represented by chemical formulas 1-6. A crystallization process can be carried out by stirring for 10 minutes to 2 hours at a temperature range of 5 to 30°C, preferably at room temperature (20 to 25°C). The time of this process can be adjusted appropriately; for example, the time can be increased when the number of repetitions of the crystallization process is small, and decreased when the number of repetitions is large.

[0093] Meanwhile, in order to crystallize more quickly, crystals of the compound represented by Formula 1 (which is a reaction product) can be added as seeds along with the solvent once or multiple times during the crystallization process. Based on 1 part by weight of the compound represented by Formulas 1-6, the seeds can be added in an amount of 0.01 parts by weight or less.

[0094] That is, when all the steps of purifying and crystallizing the reaction product in step 4 are performed sequentially to prepare the compound represented by Formula 1, step 4 may include, but is not limited to, the following steps: reacting the compound represented by Formulas 1-6 with the compound represented by Formulas 1-7 in the presence of a base; adding ethyl acetate and water to discard the aqueous layer (lower layer) and separating and extracting the organic layer (upper layer), and vacuum concentrating the purified mixture; and crystallizing the concentrate.

[0095] After the compound represented by Formula 1 is crystallized, the compound can be dried at 30 to 60°C for 8 to 14 hours to reduce the water content in the compound represented by Formula 1. More specifically, the compound can be dried at 50°C or lower.

[0096] [Beneficial Effects] As mentioned above, the preparation method according to this disclosure has the following advantages: it can prepare 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one in high yield even with a shortened process, enabling large-scale production, and improving the safety of the preparation process by using reactants that are safer than those used in conventional manufacturing methods. Detailed Description

[0097] Hereinafter, the present disclosure will be described in more detail with reference to examples. However, the following examples are for illustrative purposes only, and the scope of the present disclosure is not intended to be limited by the following examples.Furthermore, in the following embodiments, “volume” can be understood as the ratio of the volume to the weight of the starting material in each step, “parts by weight” can be understood as the weight ratio relative to the starting material in each step, and “eq” can be understood as the equivalent of each material.

[0098] Example 1: Preparation of compound represented by chemical formula 1, 13 / 19 pages, 19 CN 122341609 A

[0099] Step 1) Preparation of compounds 1-3 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (100.00 g, 1 eq) as compound 1-1 and (3S,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (122.45 g, 1.05 eq) as compound 1-2 were dissolved in a mixture of 1000.0 mL (10 volumes) of 1,4-dioxane and 10.0 mL (0.1 volumes) of purified water. Potassium tert-butoxide (179.05 g, 3 eq) was added to the mixture, and the mixture was stirred at 48 to 52 °C for 5 hours to complete the reaction.

[0100] Then, 1000.0 mL (10 volumes) of ethyl acetate and 500.0 mL (5 volumes) of purified water were added, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. 500.0 mL (5 volumes) of purified water was added to the remaining organic layer, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. 500.0 mL (5 volumes) of purified water was added to the remaining organic layer, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. The remaining organic layer was concentrated under vacuum at an external temperature of 50°C or lower by adding 200.0 mL (2 volumes) of 1,4-dioxane and azeotropically concentrated at an external temperature of 50°C or lower.

[0101] 200.0 mL (2 volumes) of 1,4-dioxane was added, and the internal temperature was raised to 40–50 °C to completely dissolve the mixture. 400.0 mL (4 volumes) of purified water was added and the mixture was stirred at room temperature for at least 1 hour. Additionally, 600.0 mL (6 volumes) of purified water was added and the mixture was stirred for at least one hour. The resulting mixture was filtered under reduced pressure using a filter and washed with 500.0 mL (5 volumes) of purified water. It was then vacuum dried at an external temperature of 50 °C for 12 hours to obtain (3S,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid tert-butyl ester (181.4 g, yield: 92.0%) as compound 1–3.

[0102] 1H NMR (500 MHz, CD3OD): δ 7.206 (s, 1H), 6.552 (s, 1H), 5.461 (s, 1H), 5.093-4.997 (d, 1H), 3.908-3.793 (d, 2H) , 3.559 (s, 2H) , 2.210 (s, 1H) , 1.926 (s, 1H) , 1.287(s, 9H).

[0103] Step 2) Preparation of Compounds 1-5: Compounds 1-3 (181.40 g, 1 eq) obtained in Step 1, 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (8.31 g, 0.04 eq), tris(dibenzylacetone)dipalladium(O) (8.96 g, 0.02 eq), and potassium tert-butoxide (164.73 g, 3 eq) were added to 907.2 mL (5 volumes) of sec-butanol and stirred at room temperature. Then, 1-ethyl-1H-pyrazole-4-amine (81.58 g, 1.5 eq) as Compound 1-4 was added, followed by 181.4 mL (1 volume) of sec-butanol, while washing the reactor walls and injection line to ensure that all remaining reagents and raw materials were used in the reaction. The resulting mixture (page 14 / 19 of the specification, 20 CN 122341609 A) was stirred at an internal temperature of 88 to 92°C for 2 hours to complete the reaction.

[0104] Then, 907.2 mL (5 volumes) of purified water and 907.2 mL (5 volumes) of ethyl acetate were added, the mixture was filtered at an internal temperature of 50°C, and washed with 907.2 mL (5 volumes) of ethyl acetate. 907.2 mL (5 volumes) of purified water was added to the filtrate again, stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then the layers were separated. The aqueous layer (lower layer) was discarded. 907.2 mL (5 volumes) of purified water was added to the remaining organic layer, stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then the layers were separated. The aqueous layer (lower layer) was discarded. Add 544.3 mL (3 volumes) of 25 wt.% sodium chloride aqueous solution to the remaining organic layer, stir for at least 30 minutes, let stand for at least 30 minutes, and then separate the layers, discarding the aqueous layer (lower layer). Filter the solution and wash with 907.2 mL (5 volumes) of ethyl acetate. Concentrate the filtrate under vacuum at an external temperature of 60°C or lower, and then add 544.3 mL (3 volumes) of ethyl acetate.The mixture was then azeotropically concentrated at an external temperature of 60°C or lower to obtain (3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid tert-butyl ester (217.9 g, yield: 100.0%) as compounds 1-5. The obtained compounds were used in the next step without purification.

[0105] Step 3) Preparation of compounds 1-6 The concentrated residue (217.9 g, 1 equivalent) of compounds 1-5 obtained in step 2 was added to and dissolved in 1090.0 mL (6 volumes) of dichloromethane. The solution was cooled to 0 to 5°C and 414.2 mL (2.28 volumes) of concentrated hydrochloric acid was slowly added so that the internal temperature did not exceed 5°C. The mixture was then stirred at 0 to 5°C for 4 hours to complete the reaction.

[0106] Then, 1090.0 mL (6 volumes) of dichloromethane and 1090.0 mL (6 volumes) of purified water were added, and the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The organic layer (lower layer) was discarded. 1090.0 mL (6 volumes) of dichloromethane was added to the remaining aqueous layer, and the mixture was stirred for 30 minutes or longer, allowed to stand for at least 30 minutes, and then separated into layers. The organic layer (lower layer) was discarded. The mixture was filtered, washed with 1090.0 mL (6 volumes) of purified water, 2179.9 mL (12 volumes) of ethyl acetate was added, and the mixture was cooled to 0 to 5°C. Then, about 1300.0 mL (7.17 volumes) of 8N sodium hydroxide solution was added to adjust the pH to 9 to 11, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. In addition, 1090.0 mL (6 volumes) of purified water was added, and the mixture was stirred for at least 30 minutes, allowed to stand for more than 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. Then, vacuum concentration was carried out at an external temperature of 50°C or lower, 654.0 mL (3.6 volumes) of methyl isobutyl ketone was added, and the mixture was concentrated azeotropically.

[0107] In addition, 1090.0 mL (6 volumes) of methyl isobutyl ketone was added, the mixture was refluxed and stirred for at least 1 hour, and then the internal temperature was cooled to 20 to 25°C. 2179.9 mL (12 volumes) of n-heptane was slowly added and stirred for 2 hours. The mixture was filtered and washed with 1090.0 mL (6 volumes) of n-heptane. The filtrate was then vacuum-dried at an external temperature of 50 °C or lower for 12 hours to obtain 126.75 g (2-step in situ yield: 75.0%) of N-(1-ethyl-1H-pyrazole-4-yl)-4-(((3S,4R)-4-fluoropiperidin-3-yl)oxy)-7H-pyrrolo[2,3-d]pyrimidine-2-amine as compounds 1-6.

[0108] 1H NMR (500 MHz, CD3OD): δ 8.902 (s, 1H), 7.906 (s, 1H), 7.528 (s, 1H), 6.932 (s, 1H), 6.277 (s, 1H), 5.375‑5.330 (d , 1H) , 5.166‑5.066 (d , 1H) , 4.104‑4.061 (d , 2H) , 3.011‑3.002 (d , 2H) , 2.826‑2.664 (dd , 2H) , 2.006‑1.776 (m, 2H) , 1.370 (s, 3H).

[0109] Step 4) Preparation of Compound 1: Compounds 1-6 (126.75 g, 1 eq, 1 part by weight) obtained in Step 3 and sodium bicarbonate (61.66 g, 2 eq) were added to a mixture of 760.5 mL (6 volumes) of tetrahydrofuran and 316.9 mL (2.5 volumes) of purified water, then cooled to 0 to 5 °C and stirred for 1 hour. Acryloyl chloride (6.54 g, 1.1 eq) as Compound 1-7 was dissolved in 190.1 mL (1.5 volumes) of tetrahydrofuran and added slowly at no more than 5 °C. After the addition was complete, the mixture was stirred at 0 to 5 °C for 2 hours to complete the reaction.

[0110] Then, 1267.5 mL (10 volumes) of purified water and 1267.5 mL (10 volumes) of ethyl acetate were added, the mixture was stirred for at least 30 minutes, allowed to stand for at least 30 minutes, and then separated into layers. The aqueous layer (lower layer) was discarded. It was filtered and washed with 380.3 mL (3 volumes) of ethyl acetate. The filtrate was concentrated under vacuum at an external temperature of 50°C or lower, and then 380.3 mL (3 volumes) of ethanol was added, and the mixture was concentrated under vacuum at an external temperature of 60°C or lower.

[0111] In addition, 316.9 mL (2.5 volumes) of ethanol was added, and the mixture was stirred at 20 to 25°C to dissolve it. 1.27 g (0.01 parts by weight) of compound 1 was added as a seed at 20 to 25°C, and the mixture was stirred for 2 hours. When precipitation had fully occurred, 63.4 mL (0.5 volumes) of ethanol was added, the flowability was checked, and the mixture was stirred for 2 hours. Then, 1140.7 mL (9 volumes) of n-heptane was added, and the mixture was stirred for 2 hours. The crystallized liquid was filtered and then washed with 253.5 mL (2 volumes) of n-heptane.After washing, the filtrate was placed in a dryer and vacuum dried at an external temperature of 50°C or lower for 10 hours to obtain 114.34 g (yield: 78%) of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)propyl-2-en-1-one as compound 1.

[0112] H NMR (500 MHz, CD3OD): δ 7.678 (s, 1H), 7.543-7.491 (d, 1H), 6.612-6.424 (m, 2H), 6.320-5.523 (m, 3H), 5.360-5.241 (m, 1H) , 5.185‑5.007 (m, 1H) , 4.709‑3.400 (m, 6H) , 2.192‑1.839 (m, 2H) , 1.358‑1.303 (m, 3H).

[0113] Comparative Example 1

[0114] Step 1) Preparation of 2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine After dissolving 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (1.0 g, 5.3 mmol) in N,N-dimethylformamide (10.0 mL), sodium hydride (234.0 mg, 5.9 mmol) was added to the mixture at 0 °C, and the mixture was stirred for 30 minutes. (2-(chloromethoxy)ethyl)trimethylsilane (975.0 mg, 5.9 mmol) was added to the reaction mixture, and then the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, followed by distilled water to separate the organic layer. The organic layer was treated with sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was separated by column chromatography to obtain 1.7 g (yield: 100.0%) of the title compound.

[0115] Step 2) Preparation of (3S,4R)-3-((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid tert-butyl ester: After dissolving (3S,4R)-4-fluoro-3-hydroxypiperidine-1-carboxylic acid tert-butyl ester (826.6 mg, 3.8 mmol) in tetrahydrofuran (10.0 mL), sodium hydride (180.9 mg, 4.5 mmol) was added to it at 0 °C and stirred for 30 minutes.2,4-Dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine (1.2 g, 3.8 mmol) was added to the reaction mixture on page 16 / 19 of the specification and stirred at room temperature for 2 hours. Ethyl acetate was added, followed by distilled water to separate the organic layer. The organic layer was treated with sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was separated by column chromatography to obtain 1.6 g (yield: 83.1%) of the title compound.

[0116] Step 3) Preparation of tert-butyl ester of (3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid: Tert-butanol (40.0 mL) was added to tert-butyl ester of (3S,4R)-3-((2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidine-1-carboxylic acid (1.4 g, 2.7 mmol) and 1-ethyl-1H-pyrazol-4-amine (333.8 mg, 3.0 mmol). Tris(dibenzylacetone)dipalladium (125.0 mg, 0.1 mmol), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (128.6 mg, 0.3 mmol), and potassium carbonate (754.6 mg, 5.5 mmol) were added, and the mixture was stirred at 150 °C for 2–3 hours and then cooled to room temperature. Ethyl acetate was added, followed by distilled water to separate the organic layer. The organic layer was treated with sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was separated by column chromatography to obtain 1.3 g (yield: 83.4%) of the title compound.

[0117] Step 4) Preparation of N-(1-ethyl-1H-pyrazol-4-yl)-4-(((3S,4R)-4-fluoropiperidin-3-yl)oxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine: A 6N hydrochloric acid solution (10.0 mL) dissolved in methanol was added to (3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-carboxylic acid tert-butyl ester (1.3 g, 2.3 mmol), and the mixture was then stirred at room temperature for 2 hours. The reaction product was concentrated, and then 1,4-dioxane (20.0 mL) and ammonia (10.0 mL) were added to the residue.The resulting mixture was stirred at room temperature for 12 hours and the reaction product was concentrated to obtain 785.8 mg (yield: 100.0%) of the title compound without further purification.

[0118] Step 5) Preparation of 1-((3S,4R)-3-((2-((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one: N-(1-ethyl-1H-pyrazol-4-yl)-4-(((3S,4R)-4-fluoropiperidin-3-yl)oxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine (785.8 mg, 2.3 mmol) and sodium bicarbonate (599.8 mg, 6.9 mmol) were dissolved in tetrahydrofuran / distilled water (15.0 mL / 3.0 mL), and then acryloyl chloride (212.7 μL, 2.6 mmol) was added at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour. Ethyl acetate was added, followed by distilled water to separate the organic layer. The organic layer was treated with sodium sulfate, filtered, and then concentrated under reduced pressure. The residue was separated by column chromatography to obtain 250.0 mg (yield: 27.5%) of the title compound 1.

[0119] 1H NMR (500 MHz, CD3OD) δ 7.98 (s, 1H), 7.57-7.55 (m, 1H), 6.88-6.45 (m, 2H), 6.30-5.98 (m, 2H), 5.80-5.44 (m, 2H), 5.20‑5.05 (m, 1H) , 4.40‑4.12 (m, 3H) , 4.05‑3.52 (m, 3H) , 2.24‑2.21 (m, 1H) , 2.01‑1.94 (m, 1H) , 1.47‑1.43 (m, 3H).

[0120] Experimental Examples The purity of the compounds represented by Formula 1 prepared by the preparation methods of the Examples and Comparative Examples is measured as follows and is shown in Table 2 below along with the yield.

[0121] (1) Method for measuring purity (related substances) When tested according to the following test method, the amount of related substances in 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one is 1.0% or less. For unknown related substances detected at a level of 0.04% or higher, the peak name is expressed in terms of relative peak retention time and the amount detected is recorded together.

[0122] 1) Diluent: Acetonitrile-purified water mixture (weight ratio 4:1) 2) Preparation of standard solution (1 time): Accurately weigh approximately 30 mg of 1-((3S,4R)-3-((2-(((1-ethyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-4-fluoropiperidin-1-yl)prop-2-en-1-one standard, place it in a 100 mL volumetric flask, add the diluent to dissolve it completely, and align it with the mark. Take an appropriate amount of the solution, filter it, and use the filtrate as the standard solution.

[0123] 3) Preparation of test solution (3 times): Accurately weigh approximately 30 mg of the drug and place it in a 100 mL volumetric flask, add the diluent to dissolve it completely, and align it with the mark. Take an appropriate amount of the solution, filter it, and use the filtrate as the standard solution.

[0124] Each solution was prepared three times and used as test solutions 1, 2, and 3.

[0125] 4) Preparation of the sensitivity confirmation solution (1 time): Accurately take 4.0 mL of the test solution and place it in a 100 mL volumetric flask. Add the diluent to dissolve it completely and align it with the mark. Accurately take 1.0 mL of the solution and place it in a 100 mL volumetric flask. Add the diluent to dissolve it completely and align it with the mark. Use this solution as the sensitivity confirmation solution.

[0126] 5) Operating conditions: Test each of the 10 μL blank solution, standard solution, and test solution under the following operating conditions according to the general test method of the Korean Pharmacopoeia using liquid chromatography.

[0127] [Operating Conditions] - Detector: UV spectrophotometer (measurement wavelength: 235 nm) - Column: X-Bridge C18 (150 x 4.6 mm, 3.5 μm) or equivalent - Flow rate: 1.0 mL / min - Injection volume: 10 μL - Column temperature: 40°C - Mobile phase: Mobile phase A1) and mobile phase B2) are controlled according to the concentration gradient shown in Table 1 below.

[0128] 1) Mobile phase A: a solution in which 1.0 mL of trifluoroacetic acid is accurately weighed at room temperature (20°C) and added and dissolved in 1000 mL of water 2) Mobile phase B: a solution in which 1.0 mL of trifluoroacetic acid is accurately weighed at room temperature (20°C) and added and dissolved in 1000 mL of acetonitrile [Table 1]

[0129] [Table 2] Specification 18 / 19 pages 24 CN 122341609 A

[0130] As shown in Table 2, it was confirmed that when the compound represented by chemical formula 1 was prepared by the preparation method of the examples, steps 2 and 3 were carried out in situ, unlike the preparation method of Comparative Example 1 (in which the prepared compound was separated and purified by column chromatography), and the compound was separated and purified by crystallization, which is beneficial for industrial production and has a better yield than Comparative Example 1.

[0131] Therefore, it is confirmed that the preparation method according to the embodiments of this disclosure enables the industrial-scale production of compounds represented by Chemical Formula 1 with high quality. Specification 19 / 19 pages 25 CN 122341609 A.

Claims

1. A method for preparing a compound represented by the following chemical formula 1, the method comprising: (Step 1) React the compound represented by the following chemical formula 1-1 with the compound represented by the following chemical formula 1-2 in the presence of a base to prepare the compound represented by the following chemical formula 1-3; (Step 2) React the compounds represented by the following chemical formulas 1-3 with the compounds represented by the following chemical formulas 1-4 in the presence of a palladium catalyst and a base to prepare the compounds represented by the following chemical formulas 1-5; (Step 3) React the compounds represented by the following chemical formulas 1-5 with an acid to prepare the compounds represented by the following chemical formulas 1-6; and (Step 4) React the compounds represented by the following chemical formulas 1-6 with the compounds represented by the following chemical formulas 1-7 in the presence of a base to prepare the compound represented by the following chemical formula 1; Wherein, at least one of steps 1 to 4 further includes a crystallization step: [Chemical Formula 1] [Chemical Formula 1-1] [Chemical Formula 1-2] [Chemical Formulas 1-3] [Chemical Formulas 1-4] [Chemical Formulas 1-5] [Chemical Formulas 1-6] [Chemical Formulas 1-7] Among them, in chemical formulas 1-1 to 1-7, P1 refers to the protecting group.

2. The preparation method according to claim 1, wherein, In step 1, the compound represented by chemical formula 1-2 is used in amounts ranging from 0.1 to 10 equivalents, based on 1 equivalent of the compound represented by chemical formula 1-1.

3. The preparation method according to claim 1, wherein In step 1, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate.

4. The preparation method according to claim 1, in, In step 1, the base is used in an amount of 0.1 to 10 equivalents based on 1 equivalent of the compound represented by chemical formula 1-1.

5. The preparation method according to claim 1, in, In step 1, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

6. The preparation method according to claim 5, in, In step 1, the reaction is carried out at 30 to 60°C.

7. The preparation method according to claim 1, in, After the compound represented by chemical formula 1-1 reacts with the compound represented by chemical formula 1-2 in the presence of a base, step 1 further includes the step of crystallizing the reaction product.

8. The preparation method according to claim 1, in, In step 2, compounds represented by chemical formulas 1-3 are used in amounts ranging from 0.1 to 10 equivalents, based on 1 equivalent of the compounds represented by chemical formulas 1-3.

9. The preparation method according to claim 1, in, In step 2, the palladium catalyst is at least one selected from the group consisting of: tris(dibenzylideneacetone)palladium(0), tetra(triphenylphosphine)palladium(0), bis[tris(2-methylphenyl)phosphine)]palladium, palladium acetate(II), 1,1-(bis(diphenylphosphine)ferrocene)palladium(II) chloride, and palladium(II) chloride.

10. The preparation method according to claim 1, in, In step 2, the base is at least one selected from the group consisting of: potassium tert-butoxide, sodium tert-butoxide, potassium methoxide, sodium methoxide, potassium tert-pentoxide, sodium tert-pentoxide, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium carbonate, calcium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, and cesium carbonate.

11. The preparation method according to claim 1, in, In step 2, the reaction is carried out in one or more organic solvents selected from the group consisting of: tetrahydrofuran (THF), 1,4-dioxane, sec-butanol, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, tert-butanol, acetone, methyl ethyl ketone, ethyl acetate, methyl tert-butyl ether, acetonitrile, toluene, xylene, heptane, 3-methyltetrahydrofuran, dichloromethane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

12. The preparation method according to claim 1, in, The reaction in step 2 is carried out at 80 to 100°C.

13. The preparation method according to claim 1, in, In step 3, the acid is at least one selected from the group consisting of: hydrochloric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, bromic acid, sulfuric acid, nitric acid, and iodic acid.

14. The preparation method according to claim 1, in, In step 3, the reaction is carried out in one or more organic solvents selected from the group consisting of: ethyl acetate, dichloromethane, butyl acetate, chloroform, methanol, ethanol, isopropanol, 1-butanol, 2-butanol, acetone, methyl ethyl ketone, methyl tert-butyl ether, acetonitrile, toluene, heptane, tetrahydrofuran, 3-methyltetrahydrofuran, 1,4-dioxane, methyl isobutyl ketone, dimethylformamide (DMF), dimethylacetamide (DMAC), and dimethyl sulfoxide (DMSO).

15. The preparation method according to claim 1, in, The reaction in step 3 is carried out at a temperature between 0°C and 50°C.

16. The preparation method according to claim 1, in, After reacting the compounds represented by chemical formulas 1-5 with an acid, step 3 further includes the step of crystallizing the reaction product.

17. The preparation method according to claim 1, in, In step 4, compounds represented by chemical formulas 1-6 are used in amounts ranging from 0.1 to 10 equivalents, based on 1 equivalent of the compounds represented by chemical formulas 1-6.

18. The preparation method according to claim 1, in, In step 4, the alkali is at least one selected from the group consisting of: potassium carbonate, sodium hydroxide, lithium hydroxide, potassium hydroxide, triethylamine, diisopropylamine, diisopropylethylamine, sodium bicarbonate, potassium bicarbonate, cesium carbonate, sodium carbonate, sodium methoxide, and potassium butyrate.

19. The preparation method according to claim 1, in, The reaction in step 4 is carried out at a temperature between -10°C and 50°C.

20. The preparation method according to claim 1, in, After reacting the compounds represented by chemical formulas 1-6 with the compounds represented by chemical formulas 1-7 in the presence of a base, step 4 further includes the step of crystallizing the reaction products.

21. A method for preparing a compound represented by the following chemical formula 1, The method includes compounds represented by the following chemical formulas 1-5 as intermediates: [Chemical Formula 1] [Chemical Formulas 1-5] Among them, in chemical formulas 1-5, P1 refers to the protecting group.

22. The preparation method according to claim 21, in, P1 is tert-butoxycarbonyl (Boc).

23. Compounds represented by the following chemical formulas 1-5, [Chemical Formulas 1-5] in, In chemical formulas 1-5, P1 refers to the protecting group.

24. The compound according to claim 23, in, P1 is tert-butoxycarbonyl (Boc).